Evidence map›Paper›PMID 37513948›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Innovative Delivery and Release Systems for Antioxidants and Other Active Substances in the Treatment of Cancer.

Zerrin Sezgin-Bayindir, Sonia Losada-Barreiro, Sofía Fernández-Bravo, Carlos Bravo-Díaz

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Zerrin Sezgin-BayindirDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara 06560, Turkey.ORCID 0000-0002-0386-7887
Sonia Losada-BarreiroDepartamento de Química-Física, Facultade de Química, Universidade de Vigo, 36200 Vigo, Spain.ORCID 0000-0002-9447-5626
Sofía Fernández-BravoOdontology Department, Primary Health Care Unit, Galician Health Service (SERGAS), Camiño do Lodairo s/n, 15570 Narón, Spain.
Carlos Bravo-DíazDepartamento de Química-Física, Facultade de Química, Universidade de Vigo, 36200 Vigo, Spain.ORCID 0000-0002-9468-0881
Universidade de Vigo · ESAnkara University · TRServicio Gallego de Salud · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the major diseases leading to death worldwide, and the fight against the disease is still challenging. Cancer diseases are usually associated with increased oxidative stress and the accumulation of reactive oxygen and nitrogen species as a result of metabolic alterations or signaling aberrations. While numerous antioxidants exhibit potential therapeutic properties, their clinical efficiency against cancer is limited and even unproven. Conventional anticancer antioxidants and drugs have, among others, the great disadvantage of low bioavailability, poor targeting efficiency, and serious side effects, constraining their use in the fight against diseases. Here, we review the rationale for and recent advances in potential delivery systems that could eventually be employed in clinical research on antioxidant therapy in cancer. We also review some of the various strategies aimed at enhancing the solubility of poorly water-soluble active drugs, including engineered delivery systems such as lipid-based, polymeric, and inorganic formulations. The use of cyclodextrins, micro- and nanoemulsions, and thermosensitive smart liposomes as useful systems for the delivery and release of poorly aqueous-soluble drugs, improving their bioactivity and stability, is also addressed. We also provide some details on their formulation processes and their use in a variety of medical applications. Finally, we briefly cover a case study specifically focused on the use of delivery systems to minimize oral cancer and associated dental problems.

Indexed as

anticancerantioxidantsbioavailabilitycontrolled releasedelivery systems

Identifiers

PMID37513948
PMCPMC10383431
OpenAlexW4385202184

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.